




For the period ended 31st August (Month 05)

Presented by	Jonathan Wilson; Chief Financial Officer
Prepared by	Justin Betts; Deputy Chief Finance Officer Amit Patel; Head of Financial Management Lubna Dharssi, Head of Financial Control Richard Allen; Head of Income and Contracts



Monthly Finance Performance Report

For the period ended 31st August (Month 05)

Key Messages

Statement of Comprehensive Income

Financial Position

For August, the trust is reporting:-

£0.37m surplus in month

- a £0.37m deficit against a planned deficit of £0.40m, an adverse variance of £0.03m; and
- a £1.47m year to date deficit against a planned deficit of £3.30m, a favourable variance of £1.84m.

Income

£22.78m in month

(including £3.05m ERF funding)

Total trust income was £25.83m in August, a favourable variance of £1.92m. Material variances include:-

- NHS Clinical activity income in August has been estimated based on draft Elective Recovery Funding (ERF) guidance and is subject to finalisation of contracts and confirmation with the ICB.
- Activity levels achieved have exceeded the trusts external activity plan required to reach the full year 118% ERF target, however they are below internal activity plans of 121%.
- Commercial patient income was £0.29m favourable to plan
- R&D income was £0.21m ahead of plan

Expenditure

£24.94m in month (pay, non-pay, excl financing)

Pay is reporting expenditure of £14.72m in August, which was £1.38m adverse to plan (£2.01m cumulatively).

The key points to note are:-

- a £0.61m provision has been made regarding historical medical locum staff Working Time Directive (WTD) obligations further to a medical staffing review process.
- Temporary staff costs were £2.13m in August excluding the medical bank pay noted above against a trend of £1.89m for the prior 12 months. Temporary staff costs remain higher than the equivalent pre-pandemic period by 40%.

Non-pay costs were £0.74m adverse against plan in August, driven by high-cost drug activity (£0.43m). Unidentified CIP contributed a further £0.26m to the adverse variance.

Financing and Depreciation

£1.26m in month

Financing is reporting a favourable variance of £0.23m in month and £1.14m YTD consisting of:-

 Interest receivable benefits linked to the trust cash balance and increases in BoE interest rates.



Cash and Working Capital Position

The cash balance as at the 31^{st} August was £58.0m, a reduction of £2.6m since the end of March 2023.

The Better Payment Practice Code (BPPC) performance in August was 99% (volume) and 99% (value) against a target of 95% across both metrics.

Capital

Capital expenditure as at 30th August totalled £16.4m predominantly due to Oriel and prior year committed expenditure against trust funded allocations.

(both gross capital expenditure and CDEL)

Trust funded capital plans are being progressed with a total of £9.7m committed expenditure against the £10.5m notified allocation. Remaining capital submissions are being reviewed and prioritised via the Capital Planning and Oversight Committee.

Other Key Information

Efficiencies

£3.56m identified v £7.8m plan

£1.37m delivered YTD £1.88m adverse The trust is reporting £1.37m efficiencies cumulatively, £1.88m adverse to plan cumulatively.

The trust has identified full year savings of £3.56m compared to a plan of £7.81m shown below.

- £1.14m Divisional efficiencies identified/forecast
- · £2.00m Productivity efficiencies identified/forecast
- £0.42m Central efficiencies including non-recurrent identified/forecast

Agency Spend

£4.08m spend YTD 5.7% total pay

Trust wide agency spend totals £4.08m YTD approximately 5.7% of total employee expenses spend, in excess of national expectations of 3.7%

• Enhanced temporary staffing oversight is being implemented trust-wide via Workforce in relation to managing and reporting agency usage and reasons.



Trust Financial Performance - Financial Dashboard Summary

FINANCIAL PERFORMANCE In Month Year to Date Financial Performance Annual Plan Plan RAG Plan % RAG £m Actual Variance Actual Variance Income £302.4m (£23.9m) (£25.8m) £1.9m £120.8m £124.3m £3.5m 3% £14.7m (£1.4m) (£68.0m) (£70.0m) (£2.0m) (3)% Pay (£162.4m) £13.3m Non Pay (£119.5m) £9.5m £10.2m (£0.7m) (£48.8m) (£49.6m) (£0.8m) (2)% Financing & Adjustments (£17.2m) £1.5m £1.3m £0.2m (£7.4m) (£6.3m) £1.1m 15% CONTROL TOTAL £3.4m (£0.4m) (£0.4m)£0.0m (£3.3m) (£1.5m) £1.8m Income includes Elective Recovery Funding (ERF) which for presentation purposes is seperated on the Statement of Comprehensive Income Memorandum Items 24% Research & Development (£0.31m) (£0.34m) (£0.03m) £0.31m 91% (£1.71m) (£1.30m) £0.41m Commercial Trading Units £5.55m (£0.09m) £0.20m £0.29m 330% £1.16m £1.93m £0.77m 66% ORIEL Revenue (£0.82m) (£0.07m) (£0.01m) £0.06m 84% (£0.34m) (£0.20m) £0.14m 41% Efficiency Schemes £7.81m £0.65m £0.38m (£0.27m) (42)% £3.25m £1.37m (£1.88m) (58)%


INCOME BREAKDOWN RELATED TO ACTIVITY

Income Breakdown			Year to Date			ı	Forecast	
£m	Annual Plan	Plan	Actual	Variance	RAG	Plan	Actual	Variance
NHS Clinical Income	£187.2m	£75.6m	£75.1m	(£0.5m)				
Pass Through	£35.1m	£14.5m	£16.4m	£1.9m				
Other NHS Clinical Income	£9.7m	£4.0m	£4.5m	£0.5m				
Commercial Trading Units	£44.4m	£17.1m	£17.5m	£0.4m				
Research & Development	£15.4m	£5.1m	£5.6m	£0.5m				
Other	£10.6m	£4.5m	£5.3m	£0.8m				
INCOME INCL ERF	£302.4m	£120.8m	£124.3m	£3.5m				

RAG Ratings Red > 3% Adverse Variance, Amber < 3% Adverse Variance, Green Favourable Variance, Grey Not applicable

PAY AND WORKFORCE

Pay & Workforce	Annual Plan		In Month					Year to Date		%
£m	Annual Plan	Plan	Actual	Variance			Plan	Actual	Variance	Total
Employed	(£160.8m)	(£13.2m)	(£11.9m)	£1.3m	-	-	(£67.3m)	(£59.0m)	£8.3m	84%
Bank	(£1.0m)	(£0.1m)	(£2.0m)	(£1.9m)	-	-	(£0.4m)	(£6.7m)	(£6.3m)	10%
Agency	(£0.0m)	-	(£0.7m)	(£0.7m)	-	-	(£0.0m)	(£4.1m)	(£4.0m)	6%
Other	(£0.5m)	(£0.0m)	(£0.0m)	(£0.0m)	-	-	(£0.2m)	(£0.2m)	(£0.0m)	0%
TOTAL PAY	(£162.4m)	(£13.3m)	(£14.7m)	(£1.4m)			(£68.0m)	(£70.0m)	(£2.0m)	




Rolling Bank & Agency Spend £m



CASH, CAPITAL AND OTHER KPI'S

Capital Programme	Annual Plan	Year to Date				Forecast			
£m	Annual Plan	Plan	Actual	Variance	RAG	Plan	Actual	Variance	
Trust Funded	(£10.5m)	(£3.6m)	(£2.8m)	(£0.8m)					
Donated/Externally funded	(£55.3m)	(£14.0m)	(£13.7m)	(£0.4m)					
TOTAL	£65.8m	£17.6m	£16.4m	(£1.2m)					

Key Metrics	Plan	Actual	RAG
Cash	41.7	58.0	
Debtor Days	45	12	
Creditor Days	45	43	
PP Debtor Days	65	47	
Use of Resources	Plan	Actual	•
Capital service cover rating Liquidity rating	-	-	
I&E margin rating	-	-	
I&E margin: distance from fin. plan	-	-	
Agency rating	-	-	
OVERALL RATING	-	-	



Trust Income and Expenditure Performance

FINANCIAL PERFORMANCE

·									
Research & Development Other Income	15.39 10.65	0.93 0.89	1.14 1.08	0.21 0.19	5.08 4.53	5.55 5.32	0.47 0.80	9% 18%	
Total Income	276.92	21.78	22.78	1.00	110.30	112.90	2.60	2%	-
Operating Expenses									_
Pay	(162.36)	(13.35)	(14.72)	(1.38)	(67.95)	(69.96)	(2.01)	(3)%	
Drugs	(40.43)	(3.33)	(3.90)	(0.57)	(16.49)	(17.79)	(1.30)	(8)%	
Clinical Supplies	(26.36)	(2.12)	(2.02)	0.09	(10.59)	(9.94)	0.64	6%	
Other Non Pay	(52.69)	(4.03)	(4.30)	(0.27)	(21.69)	(21.85)	(0.16)	(1)%	
Total Operating Expenditure	(281.83)	(22.82)	(24.94)	(2.12)	(116.72)	(119.54)	(2.82)	(2)%	_
EBITDA	(4.91)	(1.04)	(2.16)	(1.12)	(6.41)	(6.64)	(0.23)	(4)%	
Financing & Depreciation	(17.72)	(1.53)	(1.30)	0.23	(7.62)	(6.47)	1.16	15%	
Donated assets/impairment adjustments	0.52	0.04	0.04	(0.00)	0.22	0.20	(0.02)	(7)%	
Control Total Surplus/(Deficit) Pre ERF	(22.10)	(2.53)	(3.42)	(0.89)	(13.82)	(12.91)	0.91	7%	-
Elective Recovery Funding	25.51	2.12	3.05	0.92	10.52	11.44	0.92	9%	_
Control Total Surplus/(Deficit) Post ERF Income	3.40	(0.40)	(0.37)	0.03	(3.30)	(1.47)	1.84		_

Commentary



Operating Clinical activity levels recorded were 104% for Daycases, 108% for Outpatients Income First Attendances and 100% for Outpatient Procedures during August, with activity-based income totalling £16.24m. Other notable variances include:-

£1.00m favourable to plan excl ERF

- Clinical income was £16.24m, £0.16m favourable to plan;
- Commercial trading income was £3.36m, £0.29m favourable to plan.
- Research and Development income was £1.14m; £0.21m favourable to plan
- Other Income was £1.08m; £0.19m favourable to plan.

Employee Pay in August is reported as £14.72m against a cumulative trend of £13.57m in **Expenses** the prior 12 months.

£1.38m adverse to plan in month

- The in-month adverse variance relates to £0.6m of historical medical locum staff Working Time Directive (WTD) provision and, £0.5m non-delivery of efficiencies within pay,
- Substantive costs were on trend with the prior quarter.
- There was a significant increase in bank costs this month related to the medical locum provision above.
- Bank and agency costs totalled £2.13m in month against a rolling 12-month average of £1.89m.
- · Key operational areas where agency continues to be at increased levels are theatre staffing, the use agency Anaesthetists, expenditure in corporate areas (Workforce and IT) and more recently a significant increase in clinical administration.

Non-Pay Non-Pay costs in August were £11.52m against a cumulative trend of £11.03m in **Expenses** the prior 12 months.

£0.74m adverse to plan in month

> (non-pay and . financing)

- Drugs expenditure was £0.57m adverse to plan reflecting injection activity significantly higher than planned. Actual expenditure was £3.90m in month against prior month expenditure of £3.55m.
- Clinical supplies expenditure was on plan in month with actual expenditure of £2.02m in August against £2.24m in the prior month.
- Other non-pay was £0.27m adverse in month reflecting an increase unplanned consultancy and establishment expenses.

Trust Patient Clinical Activity/Income Performance

PATIENT ACTIVITY AND CLINICAL INCOME


ERF	Point of Delivery	Acti	vity In Mo	nth		Activity YTD				Weighted YTD Income £m			
		Plan	Actual	Variance	%	Plan	Actual	Variance	%	Plan	Actual	Variance	%
ΞĘ	Daycase / Inpatients	2,885	3,003	118	104%	14,282	14,944	662	105%	£22.95	£21.72	(£1.23)	
Activity	OP Firsts	10,880	11,773	893	108%	53,763	58,170	4,407	108%	£10.26	£10.53	£0.27	
ERF /	OP Procedures	18,038	17,948	(90)	100%	89,008	98,491	9,483	111%	£12.74	£14.63	£1.89	
ш	ERF Activity Total									£45.95	£46.87	£0.92	120
vity	OP Follow Ups	20,932	22,213	1,281	106%	103,522	97,870	(5,652)	95%				
Activity	High Cost Drugs Injections	4,039	4,749	710	118%	19,992	22,131	2,139	111%				
쓔	Non Elective	234	213	(21)	91%	1,155	1,092	(63)	95%				
Non EF	AandE	6,696	5,917	(779)	88%	33,046	32,422	(624)	98%				
ž	Other NHS clinical income												
	Total	63,704	65,816	2,112	103%	314,768	325,120	10,352	103%				


Income Figures Excludes CQUIN, Bedford, and Trust to Trust test income


RAG Ratings Red to Green colour gradient determined by where each percentage falls within the range


Performance % figures above, represent the Trust performance against the external activity target. Financial values shown are for ERF activity only.

ACTIVITY TREND - ERF COMPONENTS









Commentary

Activity plans and ERF

The Trust has an external Elective Recovery Fund (ERF) target of 118% for financially Weighted Activity Units (WAU) and has a stretch target of 121% in order to contribute towards the trusts efficiencies and productivity plans shown on slide eight.

The monetary values to the left are representative of activity relating to ERF activity only, and will include WAU income based on the casemix and complexity recorded.

NHS Income

NHS Patient Clinical activity income in August has been estimated based on draft Elective Recovery Funding (ERF) guidance and is subject to confirmation with the ICB.

ERF Achievement

The calculated ERF performance (against the 118% target) is estimated at £0.922m favourable variance consisting of:-

ERF Activity performance achievement

- Inpatient activity achieved 104% of activity plans in August (105% YTD);
- Outpatient Firsts Activity achieved 108% of activity plans in August (108% YTD);
- Outpatient Procedures Activity achieved 99% of activity plans in August; (111% YTD)

Non ERF Activity performance achievement

- High Cost Drugs Injections achieved 118% of activity plans in August (111% in YTD);
- **A&E** achieved 88% of activity plans in August (98% YTD);

Activity Plans

The charts to the left demonstrate the in-year activity levels compared to the previous year, including the 118% activity plans, and 2019/20 average activity levels for comparison.

The red line represents average 2019/20 activity levels.

Trust Statement of Financial Position – Cash, Capital, Receivables and Other Metrics


CAPITAL EXPENDITURE

Capital Expenditure	Annual	1	Year to Da	te
£m	Plan	Plan	Actual	Variance
Estates - Trust Funded	5.1	1.9	1.2	(0.7)
Medical Equipment - Trust Funded	1.4	0.4	0.6	0.1
IT - Trust Funded	1.2	1.0	1.0	0.0
ORIEL - Trust Funded	-	-	-	-
Commercial - Trust funded	0.7	-	0.1	0.1
Other - Trust funded	2.1	0.2	(0.0)	(0.2)
TOTAL - TRUST FUNDED	10.5	3.6	2.8	(8.0)
Externally funded	55.3	14.0	13.7	(0.4)
TOTAL INCLUDING DONATED	65.8	17.6	16.4	(1.2)

Capital Funding £m	Annual Plan	Secured	Not Yet Secured	% Secured
4111	1 IUII		occurca	Occurca
ICS Fair Share Allocation	10.5	10.5	(0.0)	100%
Cash Reserves - Oriel	-	-		-
Cash Reserves - B/Fwd	-	-		-
Capital Loan Repayments	-	-		-
TOTAL - TRUST FUNDED	10.5	10.5	(0.0)	100%
Externally funded	55.1	53.9	1.2	98%
Donated/Charity	0.2	0.2		100%
TOTAL INCLUDING DONATED	65.8	64.6	2%	98%

RECEIVABLES

Net Receivables £m	0-60 Days	60-180 Days	180+ Days	2020/21	Total
ICB Debt	(0.3)	(0.9)	(0.0)	(0.0)	(1.2)
Other NHS Debt	1.3	(0.9)	0.4	0.4	1.2
Non NHS Debt	1.1	1.0	1.1	0.8	4.0
Commercial Unit Debt	3.2	1.3	0.7	0.3	5.4
TOTAL RECEIVABLES	5.3	0.5	2.1	1.4	9.4



STATEMENT OF FINANCIAL POSITION

Statement of Financial	Annual		Year to Da	te
Position £m	Plan	Plan	Actual	Variance
Non-current assets	262.8	226.0	223.7	(2.4)
Current assets (excl Cash)	33.9	33.9	26.0	(7.9)
Cash and cash equivalents	57.1	41.7	58.0	16.3
Current liabilities	(68.2)	(68.4)	(72.7)	(4.3)
Non-current liabilities	(66.9)	(61.6)	(61.7)	(0.0)
TOTAL ASSETS EMPLOYED	218.6	171.6	173.3	1.7

OTHER METRICS

Use of Resources	Weighting	Plan YTD	Score
Capital service cover rating	20%	-	-
Liquidity rating	20%	-	-
I&E margin rating	20%	-	-
I&E margin: distance from financial pla	20%	-	-
Agency rating	20%	-	-
OVERALL RATING		-	-

Commentary

Working Capital

Cash and The cash balance as at the 31st August was £58.0m, a reduction of £2.6m since the end of March 2023.

Capital Capital expenditure as at 31st August totalled £16.4m Expenditure predominantly due to Oriel and prior year committed expenditure against trust funded allocations.

> Trust funded capital plans are being progressed with a total of £9.7m committed expenditure against the £10.5m notified allocation.

> · The remaining capital sums are being reviewed and prioritised via the Capital Planning and Oversight Committee are forecast to spend up to the notified capital level.

Receivables have halved to £9.4m since the end of the 2022/23 financial year. Debt in excess of 60 days reduced by £1.0m in September, with a small increase of £0.1m in current debt.

Payables totalled £14.1m at the end of August, a reduction of £10.3m since the end of March 2023.

The trust's performance against the Better Payment Practice Code (BPPC) was 99% (volume) and 99% (value) against a target of 95%. Prior month achievement was 99% (volume) and 99% (value).

Resources suspended.

Use of Use of resources monitoring and reporting has been

Trust Statement of Financial Position – Cashflow

Cash Flow £m	Apr Actuals	May Actuals	Jun Actuals	Jul Actuals	Aug Actuals	Sep Forecast	Oct Forecast	Nov Forecast	Dec Forecast	Jan Forecast	Feb Forecast	Mar Forecast	Outturn Total	Aug Forecast	Aug Var
Opening Cash at Bank	60.6	59.8	58.8	59.8	61.7	58.0	51.9	64.0	66.8	56.7	60.5	62.5	60.6		
Cash Inflows															
Healthcare Contracts	19.6	18.5	24.0	20.4	18.9	18.8	21.2	21.2	15.1	21.2	20.2	18.6	237.6	18.9	0.0
Other NHS	5.3	0.8	5.1	3.3	1.3	0.8	0.8	8.0	8.0	8.0	0.8	0.8	21.1	8.0	0.6
Moorfields Private/Dubai/NCS	3.0	4.3	3.5	3.3	3.3	3.5	3.8	3.9	3.0	3.7	3.6	3.8	42.9	3.0	0.3
Research	1.2	1.0	0.7	0.9	8.0	0.9	1.6	1.6	1.6	1.6	1.6	1.6	14.9	0.9	(0.2)
VAT	0.6	0.4	0.4	-	1.3	0.5	0.5	0.5	0.5	0.5	0.5	0.5	6.3	0.5	0.8
PDC	-	-	-	-		-	5.0	5.0	5.0	5.0	5.0	5.0	30.0	-	-
Other Inflows	8.0	0.4	0.2	8.0	0.2	0.3	10.3	0.3	0.3	0.3	0.3	0.3	14.1	0.3	(0.0)
Total Cash Inflows	30.5	25.4	33.9	28.7	25.9	24.7	43.2	33.1	26.1	33.0	31.9	30.5	367.0	24.3	1.6
Cash Outflows															
Salaries, Wages, Tax & NI	(10.9)	(11.6)	(14.4)	(13.5)	(11.7)	(12.0)	(12.0)	(12.0)	(12.0)	(12.0)	(12.0)	(12.0)	(146.1)	(12.0)	0.3
Non Pay Expenditure	(15.7)	(12.3)	(15.4)	(11.6)	(14.7)	(9.1)	(11.4)	(11.5)	(9.6)	(11.7)	(11.7)	(13.4)	(148.2)	(10.9)	(3.8)
Capital Expenditure	(2.7)	(1.1)	(1.3)	(0.6)	(8.0)	(3.0)	(1.0)	(1.0)	(1.0)	(1.0)	(1.0)	(5.4)	(20.0)	(1.0)	0.3
Oriel	(0.2)	(0.2)	(0.4)	(0.1)	(0.3)	(3.6)	(4.8)	(3.9)	(11.8)	(2.8)	(2.9)	(2.6)	(33.5)	(2.3)	2.0
Moorfields Private/Dubai/NCS	(1.8)	(1.2)	(1.5)	(1.0)	(1.5)	(1.8)	(1.8)	(1.8)	(1.8)	(1.8)	(1.8)	(1.8)	(19.6)	(1.8)	0.3
Financing - Loan repayments	-	-	-	-	(0.6)	(0.5)	-	-	-	-	(0.4)	(0.5)	(2.0)	(0.4)	(0.2)
Dividend and Interest Payable	-	-	-	-	-	(0.9)	-	-	-	-	-	(0.9)	(1.8)	-	-
Total Cash Outflows	(31.3)	(26.4)	(32.9)	(26.8)	(29.5)	(30.9)	(31.1)	(30.2)	(36.2)	(29.3)	(29.9)	(36.5)	(371.2)	(28.4)	(1.1)
Net Cash inflows /(Outflows)	(0.7)	(1.0)	1.0	1.8	(3.6)	(6.2)	12.1	2.9	(10.1)	3.7	2.0	(6.1)	-	(4.1)	0.4
Closing Cash at Bank 2023/24	59.8	58.8	59.8	61.7	58.0	51.9	64.0	66.8	56.7	60.5	62.5	56.4	56.4		
Closing Cash at Bank 2023/24 Plan	53.9	50.0	47.2	44.9	41.4	49.8	52.4	55.9	46.3	50.6	53.1	56.4	56.4		
Closing Cash at Bank 2022/23	74.7	71.9	73.0	74.8	75.7	75.8	74.7	73.5	76.1	70.3	71.2	60.6	60.6		



Commentary


Cash flow The cash balance as at the 31st August 2023 was £58.0m, a reduction of £2.6m since the end of March 2023.

> The current financial regime has resulted in block contract payments which gives some stability and certainty to the majority of cash receipts. The trust currently has 80 days of operating cash (prior month: 85 days).

> August saw a cash outflow of £3.6m against a forecast outflow of £4.1m due to slightly higher than planned receipts, and lower than expected capital payments. The cash flow forecast for the end of the financial year is showing achievement of plan.


Trust Efficiency Scheme Performance

EFFICIENCY SCHEMES PERFORMANCE In Month Year to Date Forecast Efficiency Schemes Annual Plan Actual Variance Plan Actual Variance Actual Variance City Road £1.59m £0.13m £0.05m (£0.08m) £0.66m £0.22m (£0.45m)£1.59m £0.49m (£1.10m) North £1.09m £0.09m £0.01m (£0.08m) £0.45m £0.06m (£0.39m) £1.09m £0.09m (£1.00m)South £0.72m £0.06m £0.03m (£0.03m)£0.30m £0.08m (£0.22m)£0.72m £0.10m (£0.61m)Ophth. & Clinical Serv. £0.10m £0.03m (£0.06m) £0.48m £0.09m (£0.38m) £1.14m £0.25m £1.14m (£0.90m) Estates & Facilities £0.01m £0.04m £0.00m (£0.04m) £0.21m (£0.19m) £0.49m £0.04m (£0.45m)£0.49m Corporate £0.77m £0.06m £0.02m (£0.05m)£0.32m £0.09m (£0.23m)£0.77m £0.17m (£0.60m) **DIVISIONAL EFFICIENCIES** £5.81m £0.48m £0.15m (£0.34m) £2.42m £0.55m (£1.87m) £5.81m £1.14m (£4.67m) Central Productivity/Activity @ 121% £2.00m £0.17m £0.19m £0.03m £0.83m £0.64m (£0.19m) £2.00m £2.00m Other/Non Recurrent schemes £0.04m £0.04m £0.18m £0.18m £0.42m £0.42m TRUST EFFICIENCIES £7.81m £0.65m £0.38m (£0.27m) £3.25m £1.37m (£1.88m) £7.81m £3.56m (£4.25m)





TRUST WIDE FORECAST

DIVISIONAL REPORTING & OTHER METRICS



* charts may include rounding differences





Commentary

Trust efficiencies are managed and reported via the CIP Board.

Identified The divisional reporting segment highlights the level of Savings identified schemes by division and the corresponding risk profile for these schemes.

Delivery

In Year The trust is reporting efficiency savings achieved of:-

£0.38m in month, compared to a plan of £0.65m, a

- £0.27m adverse variance; • £1.37m year to date, compared to a plan of £3.25m,
- £1.88m adverse to plan.

Productivity Productivity efficiency schemes represent the level of ERF activity performance in excess of the external 118% activity target, by financial weighted average income, less the estimated level of costs of delivery within clinical divisions.

- The Trust has set baseline internal activity targets of 121%+, which subject to case mix and national quidance could represent £3.0m additional income* prior to identified marginal costs of delivery.
- Current assumption include a net £2m forecast contribution whilst activity recovery plans are assessed.

Risk Profiles The charts to the left demonstrates the identified saving by category, divisional identification status including risk profiles, and the Trust wide monthly risk profile changes for identified schemes as the year progresses.

Forecast The trust is currently forecasting to achieve £3.56m of savings against the £7.81m plan, some £4.25m adverse to planned efficiency levels.

* Subject to finalisation of national ERF guidance, contracts and confirmed payment status (awaited as at 31st August 2023)